Pathological analysis of nervous system tissues remains the standard for defining neurodegenerative diseases, monitoring their progression, and evaluating the effects of experimental or therapeutic manipulations. Imaging is critical for performing neuropathological analyses and has emerged as a powerful independent approach for investigating dynamic physiological and pathophysiological processes. The proposed program project will take maximal advantage of these valuable approaches. Accurate pathological analyses requires the expert handling and preparation of cells and tissues for study and can require the skills of a trained neuropathologist to interpret the findings. Effective application of imaging approaches requires well-maintained state-of-the-art equipment, ample opportunities for education and training, and the availability of expert consultancy. The main goals of this core are to provide the resources to project leaders of this program and enable them to address their research questions efficiently and conclusively with imaging and neuropathology approaches. To accomplish these goals, the Microscopy and Neuropathology Core proposes:
Aim 1, to assist program members with the fixation and processing of brain tissues and neural cultures;
Aim 2, to perform routine histological staining of cells and tissues and support immunostaining required for neuropathological studies;
Aim 3, to assist and train program members in the microscopic imaging and digital documentation of their imaging data;
Aim 4, to provide assistance with quantitative image analysis of morphological and immunolabeling data;
and Aim 5, to establish a tissue/section bank and maintain a corresponding online database with Core A that is accessible to all projects.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG022074-09
Application #
8286963
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
9
Fiscal Year
2011
Total Cost
$278,940
Indirect Cost
Name
J. David Gladstone Institutes
Department
Type
DUNS #
099992430
City
San Francisco
State
CA
Country
United States
Zip Code
94158
Valera, Elvira; Spencer, Brian; Mott, Jennifer et al. (2017) MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy. Front Mol Neurosci 10:329
Valera, Elvira; Spencer, Brian; Fields, Jerel A et al. (2017) Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. Acta Neuropathol Commun 5:2
Overk, Cassia; Masliah, Eliezer (2017) Perspective on the calcium dyshomeostasis hypothesis in the pathogenesis of selective neuronal degeneration in animal models of Alzheimer's disease. Alzheimers Dement 13:183-185
Spencer, Brian; Desplats, Paula A; Overk, Cassia R et al. (2016) Reducing Endogenous ?-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model. J Neurosci 36:7971-84
Spencer, Brian; Kim, Changyoun; Gonzalez, Tania et al. (2016) ?-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Hum Mol Genet 25:1100-15
Valera, Elvira; Masliah, Eliezer (2016) Therapeutic approaches in Parkinson's disease and related disorders. J Neurochem 139 Suppl 1:346-352
Spencer, Brian; Potkar, Rewati; Metcalf, Jeff et al. (2016) Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease. J Biol Chem 291:1905-20
Valera, E; Monzio Compagnoni, G; Masliah, E (2016) Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy. Neuropathol Appl Neurobiol 42:95-106
Valera, Elvira; Spencer, Brian; Masliah, Eliezer (2016) Immunotherapeutic Approaches Targeting Amyloid-?, ?-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics 13:179-89
Valera, Elvira; Masliah, Eliezer (2016) Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord 31:225-34

Showing the most recent 10 out of 254 publications